Literature DB >> 2665975

Studies of humoral and cell-mediated immunity to peptides shared by HLA-27.1 and Klebsiella pneumoniae nitrogenase in ankylosing spondylitis.

N Tsuchiya1, G Husby, R C Williams.   

Abstract

One-hundred and twenty-four patients with spondylarthropathies were studied for antibodies to the peptides from HLA-B27.1 and Klebsiella pneumoniae nitrogenase which share a QTDRED hexamer sequence. Of 60 male Norwegian ankylosing spondylitis (AS) patients 23.3% showed positive ELISA reactivity for B27.1 peptide compared with 4% of Norwegian male controls (P less than 0.10). This difference was not observed among patients and controls from New Mexico. All patients with anti-B27.1 antibody were HLA-B27+. Antibody to B27.1 peptide was present in 20% of normal female controls with at least one previous pregnancy. No female control without previous pregnancy showed positive anti-B27.1 peptide reactivity. Anti-Klebsiella peptide antibody was neither significantly elevated in AS nor correlated with anti-B27.1 peptide antibody. Significant migration inhibition by these peptides was not observed in AS or normal controls. The possible influence of epitope conformation, rather than sequence homology, in potentially cross-reacting determinants shared by bacterial antigens and human Class I molecules requires further study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665975      PMCID: PMC1541881     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

Review 1.  HLA-A, -B and -C antigens, their serology and cross-reaction.

Authors:  V C Joysey; E Wolf
Journal:  Br Med Bull       Date:  1978-09       Impact factor: 4.291

2.  Evidence for a specific B27-associated cell surface marker on lymphocytes of patients with ankylosing spondylitis.

Authors:  K Seager; H V Bashir; A F Geczy; J Edmonds; A de Vere-Tyndall
Journal:  Nature       Date:  1979-01-04       Impact factor: 49.962

3.  Reiter's disease and HL-A 27.

Authors:  D A Brewerton; M Caffrey; A Nicholls; D Walters; J K Oates; D C James
Journal:  Lancet       Date:  1973-11-03       Impact factor: 79.321

4.  Ankylosing spondylitis and HL-A 27.

Authors:  D A Brewerton; F D Hart; A Nicholls; M Caffrey; D C James; R D Sturrock
Journal:  Lancet       Date:  1973-04-28       Impact factor: 79.321

Review 5.  Solid-phase peptide synthesis.

Authors:  R B Merrifield
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1969

6.  Leukocyte migration agarose technique: some technical details.

Authors:  J E Clausen
Journal:  Acta Allergol       Date:  1973-12

7.  Association between ankylosing spondylitis and a 9.2 kb Pvu II class I HLA DNA restriction fragment: a reassessment.

Authors:  J P Durand; J D Taurog
Journal:  J Rheumatol       Date:  1988-07       Impact factor: 4.666

8.  Ankylosing spondylitis: klebsiella and HL-A B27.

Authors:  R Ebringer; D Cooke; D R Cawdell; P Cowling; A Ebringer
Journal:  Rheumatol Rehabil       Date:  1977-08

9.  Ankylosing spondylitis, HLA-B27 and Klebsiella. I. Cross-reactivity studies with rabbit antisera.

Authors:  J Welsh; H Avakian; P Cowling; A Ebringer; P Wooley; G Panayi; R Ebringer
Journal:  Br J Exp Pathol       Date:  1980-02

10.  Ankylosing spondylitis, HLA-B27 and Klebsiella. II. Cross-reactivity studies with human tissue typing sera.

Authors:  H Avakian; J Welsh; A Ebringer; C C Entwistle
Journal:  Br J Exp Pathol       Date:  1980-02
View more
  10 in total

1.  How does HLA-B27 confer susceptibility to inflammatory arthritis?

Authors:  J S Gaston
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

2.  Antibodies to the peptide from the plasmid-coded Yersinia outer membrane protein (YOP1) in patients with ankylosing spondylitis.

Authors:  N Tsuchiya; G Husby; R C Williams
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

Review 3.  Molecular mimicry--hypothesis or reality?

Authors:  N Tsuchiya; R C Williams
Journal:  West J Med       Date:  1992-08

4.  HLA-B27 determination using serological methods. A comparison of enzyme immunoassay and a microlymphocytotoxic test with flow cytometry and a molecular biological assay.

Authors:  A Dunky; J Neumüller; C Hübner; G F Fischer; P M Bayer; E Wagner; D W Schwartz; W R Mayr
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 5.  HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?

Authors:  J H Ringrose
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

6.  Autoantibodies to the HLA-B27 sequence cross-react with the hypothetical peptide from the arthritis-associated Shigella plasmid.

Authors:  N Tsuchiya; G Husby; R C Williams; H Stieglitz; P E Lipsky; R D Inman
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

7.  Epitope mapping of an HLA-B27 monoclonal antibody that also reacts with a 35-kD bacterial outer-membrane protein.

Authors:  A Toubert; M Hamachi; C Raffoux; M S Park; D T Yu
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

8.  Absence of autoantibodies to peptides shared by HLA-B27.5 and Klebsiella pneumoniae nitrogenase in serum samples from HLA-B27 positive patients with ankylosing spondylitis and Reiter's syndrome.

Authors:  D D de Vries; A J Dekker-Saeys; E Gyodi; U Bohm; P Ivanyi
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

9.  A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution.

Authors:  R H Scofield; W L Warren; G Koelsch; J B Harley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

10.  Short peptide sequence identity between human viruses and HLA-B27-binding human 'self' peptides.

Authors:  Shipeng Sun; Tao Wang; Bo Pang; Huamin Wei; Guijian Liu
Journal:  Theory Biosci       Date:  2013-12-22       Impact factor: 1.315

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.